Lionco Pharmaceutical Group Co.,Ltd. (SHA:603669)
6.05
+0.15 (2.54%)
Aug 20, 2026, 3:00 PM CST
SHA:603669 Revenue
Lionco Pharmaceutical Group had revenue of 170.92M CNY in the quarter ending June 30, 2026, with 40.69% growth. This brings the company's revenue in the last twelve months to 408.33M, down -0.38% year-over-year. In the year 2025, Lionco Pharmaceutical Group had annual revenue of 322.48M, down -15.09%.
Revenue (ttm)
408.33M
Revenue Growth
-0.38%
P/S Ratio
10.42
Revenue / Employee
1.44M
Employees
284
Market Cap
4.26B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 322.48M | -57.30M | -15.09% |
| Dec 31, 2024 | 379.78M | 182.95M | 92.95% |
| Dec 31, 2023 | 196.83M | -92.43M | -31.95% |
| Dec 31, 2022 | 289.26M | -451.06M | -60.93% |
| Dec 31, 2021 | 740.33M | -260.67M | -26.04% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Shenzhen Neptunus Bioengineering | 25.24B |
| Jianmin Pharmaceutical Group | 3.35B |
| Jinling Pharmaceutical Company | 3.16B |
| Hunan Fangsheng Pharmaceutical | 1.79B |
| Tianjin Lisheng Pharmaceutical | 1.35B |
| LanZhou Foci Pharmaceutical | 910.98M |
| Harbin Medisan Pharmaceutical | 813.23M |
| Newland Pharmaceutical | 659.54M |